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Abstract
Leukaemia is often associated with genetic alterations such as translocations, amplifications and deletions, and recurrent
chromosome abnormalities are used as markers of diagnostic and prognostic relevance. However, a proportion of acute
myeloid leukaemia (AML) cases have an apparently normal karyotype despite comprehensive cytogenetic analysis. Based on
conventional cytogenetic analysis of banded chromosomes, we selected a series of 23 paediatric patients with acute
myeloid leukaemia and performed whole genome array comparative genome hybridization (aCGH) using DNA samples
derived from the same patients. Imbalances involving large chromosomal regions or entire chromosomes were detected by
aCGH in seven of the patients studied. Results were validated by fluorescence in situ hybridization (FISH) to both interphase
nuclei and metaphase chromosomes using appropriate bacterial artificial chromosome (BAC) probes. The majority of these
copy number alterations (CNAs) were confirmed by FISH and found to localize to the interphase rather than metaphase
nuclei. Furthermore, the proliferative states of the cells analyzed by FISH were tested by immunofluorescence using an
antibody against the proliferation marker pKi67. Interestingly, these experiments showed that, in the vast majority of cases,
the changes appeared to be confined to interphase nuclei in a non-proliferative status.
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Introduction
Acute myeloid leukaemia is a heterogeneous disease from both
clinical and molecular points of view [1]. The majority of AML
patients (both paediatric and adult) show specific chromosome
rearrangements that can be detected using conventional methods
of chromosome banding and the identification of these chromo-
some abnormalities impacts upon both the diagnosis and prognosis
of leukaemia patients [2–5].
In the clinical diagnostic setting, conventional cytogenetics by
chromosome banding detects chromosomal abnormalities in the
majority of AML patients. However, even a decade ago a normal
karyotype was observed in a high number of cases, up to
approximately 40% of all patients. In paediatric patients, the
proportion of cases with no detectable abnormal clone is
considered only approximately 20% [2,6]. This proportion is
even lower when considering the fact that a number of
submicroscopic genetic alterations have been uncovered. Exam-
ples of these are MLL partial tandem duplication [7], mutations of
the transcription factor C/EBPa [8], mutations of the FLT3 gene
[9] and mutation in the NPM1 protein [10].
These submicroscopic changes have an impact on prognosis
that challenges the general concept that normal karyotype AML is
usually associated with an intermediate prognostic value [2,11].
The advent of aCGH technology has improved substantially the
detection of genomic imbalances in cancer, allowing the
identification of new candidate genes [12]. Recently aCGH has
identified cryptic copy number alterations (CNAs) in AML
patients with complex karyotypes [13], with known chromosomal
abnormalities [14] and in 15–16% of adult cases with normal
karyotypes [15,16]. These abnormalities consist of small gains or
losses of genomic material ranging in size from 0.2 to 4.1 Mb, with
losses usually more common than gains [14–16].
To investigate further the role of CNAs in AML, we set out to
identify alterations that might have been missed by cytogenetic
analysis of banded chromosomes in a cohort of AML patients with
reported normal or incomplete karyotypes. We used a genome-
wide aCGH platform, with a probe spacing of ,1 Mb, to analyze
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DNAs from 23 paediatric AML cases. We performed FISH to
both interphase nuclei and metaphase chromosomes to verify the
changes found by aCGH. Moreover, in a selected number of
patients we investigated the proliferative status of the leukaemic
cells to determine whether the chromosomal abnormalities
identified might be confined to proliferating or non-proliferating
cells.
Results
Discovery of large cryptic CNAs in paediatric AML
patients with normal karyotypes
A total of 23 paediatric patients with AML and reported normal
karyotype were analyzed for CNAs by aCGH. The karyotypes had
been assessed previously either by Q-banding (patient nos. 1–5) or
by G-banding (patient nos. 6–23). A number of 20 metaphases
were analyzed for each patients, when possible, before a diagnosis
of normal karyotype was made. In patients no. 1–3, 5 and 18,
diagnosis of normal karyotype was made based on the analysis of
the few metaphases that were retrieved from the samples (,20).
The clinical and cytogenetic data for the patients and the aCGH
results are documented in Table 1 and described according to the
International System for Human Cytogenetic Nomenclature [17].
In total, 15 large CNAs were identified in seven of the 23
paediatric patient samples; gains were detected in six of the seven
cases and losses in three cases, the majority involving entire
chromosomes or large chromosomal regions. To summarize the
aCGH results: three copies of chromosome 7 and three copies of
chromosome 8 were detected in patient no. 1; three copies of
chromosome 19 were detected in patient no. 2; a gain of
1p36.2p32.3 together with a gain of 11q12.3q13.4 were detected
in patient no. 4; a gain of regions 1p36.2p32.3, 9q33.3q34.3,
13q34 and 22q13.1q13.3 were detected in patient 5; a loss of
7q31.2q36.3 and 16p12.2p12.1 together with a gain of
8q24.12q24.3 were detected in patient no. 11; a loss of
15q13.3q21.1 was detected in patient 12 and a loss of 4q35.2
together with a gain of 13q31.1q33.1 were detected in patient
no. 19 (Table 1). One of the gains, the 13q34 gain noted in patient
no. 5, encompassed a region of polymorphism documented in the
Database of Genomic Variants (DGV) and was excluded from
follow-up studies. The remaining 16 samples revealed small
putative aberrations that were also excluded from the follow-up
Table 1. Clinical and cytogenetic data of the paediatric and adult patients with AML and no reported chromosomal abnormalities
analyzed in the present study.
Pt Age/gender Disease Karyotype
no. of
metaphases
analyzed % Blasts Revised abnormalities after aCGH
1 4y/M AML-M1 46,XY 15 86 arr 7(1–158,821,424)x3,arr 8(1–146,274,826)x3
2 10y/M AML-M1 46,XY 12 75 arr 19(1–63,811,651)x3
3 0.9mo/F AML-M5a 46,XX 10 98
4 12y/F AML-M5a 46,XX 20 90 arr 1p36.2p32.3(1–53,386,269)x3*,arr11q12.3q13.4(62,515,049–
70,795,221)x3*
5 11y/M AML-M5b 46,XY 10 75 arr 1p36.2p32.3(1–53,386,269)x3*,arr 9q33.3q34.3(127,088,200-
141,213,431)x3,arr 13q34(112,590,255-115,169,878)x3,arr
22q13.1q13.3(38,481,453-49,928,069)x3*
6 4y1mo/M AML-M4 46,XY 31 .90
7 15y3mo/M AML-M6 46,XY 32 .90
8 11y/F AML-M4 46,XX 20 .90
9 12y5mo/M AML 46,XY 33 .90
10 8mo/F AML-M7 46,XX 30 .90
11 16y1mo/F AML-M2 46,XX 33 .90 arr 7q31.2q36.3(116,864,746-156,509,391)x1,arr
8q24.12q24.3(119,730,121–
146,195,298)x3,arr 16p12.2p12.1(21,397,775-26,819,858)x1
12 11y/F AML-M4 46,XX 29 .90 arr 15q13.3q21.1(31,421,666-49,223,905)x1
13 14y9mo/M AML-M4 46,XY 29 .90
14 9y/M AML 46,XY 34 .90
15 12y1mo/F AML 46,XX 45 .90
16 4y1mo/M AML-M4 46,XY 38 .90
17 3y1mo/F AML-M1 46,XX 25 .90
18 12y7mo/F AML 46,XX 12 .90
19 7y5mo/F AML 46,XX 31 .90 arr 4q35.2(188,285,250-190,782,221)x1,arr
13q31.1q33.1(85,885,263-104,566,220)x3
20 17y9mo/M AML-M2 46,XY 34 .90
21 15y3mo/M AML 46,XY 34 .90
22 2y10mo/F AML 46,XX 36 .90
23 6y10mo/F AML-M2 46,XX 23 .90
*copy number abnormalities not verified by FISH.
doi:10.1371/journal.pone.0020607.t001
aCGH Study of Paediatric AML
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studies. Examples of the plots showing the CNAs detected in
patients no. 1 and no. 11 are shown in Figure 1.
FISH studies
Verification of CNAs identified by aCGH. Ten of the
putative CNAs identified by aCGH were investigated further by
FISH, using probes specifically targeted to the chromosomes
involved in the abnormalities. Importantly, the cell preparations
used for FISH were derived from samples obtained at the same
time as those used for DNA extraction for the aCGH experiments.
The BAC clones used for FISH are listed in Table 2 together with
a summary of the results showing that ten putative CNAs were
verified by FISH. Examples of FISH images obtained using
samples from patients no. 1, 2, 5, 11, 12 and 19 are shown in
Figure 2.
Cell to cell pattern of mosaicism. For all of the 10 CNAs
verified by FISH, the FISH analyses also revealed that the cell
population assayed was mosaic for the abnormalities.
Furthermore, the CNAs appeared to be confined to the
interphase nuclei and were not observed in any of the
metaphases noted during this set of analysis (Figure S1). In two
cases, patient no. 1 and no. 19, who had more than one CNA,
dual-colour FISH experiments were carried out to investigate
whether the CNAs were occurring within the same interphase
cells, or whether they were differentially distributed across cells
(Figures 2A and 2H, respectively). For patient no. 1, 14/50 (28%)
of the interphase nuclei gave 3 red signals for chromosome 7 and 3
green signals for chromosome 8 in the same nucleus, whereas only
3/50 (6%) of interphase nuclei appeared to carry only a single
extra chromosome 8. For patient no. 19, 92/152 (60.5%)
interphase nuclei gave three green signals for chromosome 13
and one red signal for chromosome 4 occurring within the same
interphase cells.
Proliferation experiment. In order to determine if the
interphase cells carrying the chromosomal abnormalities were
proliferating or non-proliferating/quiescent, immunofluorescence
with an antibody specific for the proliferation marker pKi-67 was
performed in combination with FISH. Anti-pKi-67 antibodies
decorate the nucleolus in proliferating cells and also associate with
heterochromatic regions in G1 cells [18,19]. In cases where more
than one CNA was present, only one representative FISH probe,
randomly selected, was used. A total of four paediatric patient
samples were tested in this way and in each case at least 200
interphase cells were scored. The results described in Table 3 show
that, for each case, the proliferative state of the cells carrying the
CNA was different from that of the cells that were not carrying the
CNA. For the CNA cells, the average of non-proliferating (pKi-67
negative) cells was 96.75% (based on 4 patient samples ranging
from 94–100%) compared with an average of 72.25% of cells that
did not carry CNAs (based on 4 patient samples ranging from 69–
75%). For all patients, the difference in cell percentages between
the non-proliferating cells without CNAs (2 signals) and the non-
proliferating cells with CNAs (3 signals) is statistically significant.
Indeed, if a one-tailed hypothesis test is performed on the
difference in population proportions, then the result is significant
even at 99% confidence.
Importantly, during these experiments at least 3 metaphases per
sample were also identified and scored. As expected, all were
positive for pKi-67, since pKi-67 forms a coat around metaphase
chromosomes [19]. However, in contrast to the previous FISH
experiments where no abnormalities were observed in the
metaphase cells analyzed, two of the six metaphases analyzed in
patient no. 1 were this time observed to carry trisomy 7 (Figure 3).
Thus, including the original FISH results where seven metaphases
could be scored, a total of two out of thirteen (15%) metaphases
scored for patient no. 1 carried trisomy 7.
Discussion
In this study, we tested, by aCGH, a series of paediatric AML
patient samples with normal karyotypes to assess the contribu-
tion of cryptic CNAs in this cohort. The definition of normal
karyotype was based on the analysis of at least 20 metaphases in
the majority of cases. It should be noted that in five cases only
10–15 metaphases were analyzed and in three of these cases
CNAs were detected. However, in the UK 10–19, metaphases
with no chromosomal abnormalities still mandates a normal
karyotype result, albeit with a statement about low level clones.
Clinically these patients would all be in the same prognostic
group. The current recommendations for standardization of
criteria in AML, include that at least 20 metaphases are
required for the assessment of a normal karyotype [20].
However, it should be noted that the samples reported in this
study were analysed prior to the current guidelines (2003–2006),
when the criteria were still unclear. Furthermore, in four cases
CNAs were found in patients where more than 20 metaphases
had been analysed.
To understand the biological origin of the CNAs, we undertook
further characterization using FISH and cell proliferation tests. Of
the 23 paediatric patients tested, we identified and confirmed large
CNAs in seven cases (30%), three of whom carried more than one
abnormality.
In these cases the CNAs were noted as large because they
encompassed at least one chromosomal band. CNAs that were
defined by less than three contiguous clones were generally excluded.
For the remaining 10 CNAs that were verified by FISH, all
except the 4q35.2 loss (patient no. 19) were in chromosomal
regions that have been reported previously (either wholly or partly)
in patients with AML.
Furthermore, for the 10 CNAs that were verified by FISH, a
mosaic pattern of hybridization was noted and most significantly,
the CNAs were discovered to be confined to the interphase nuclei
in all but one case. In this case (patient no. 1), the combined FISH
and indirect immunofluorescence assay showed changes in two of
the 13 metaphases that could be analyzed.
These results gave an important insight into why the CNAs
were likely to have been missed when the patients’ chromosome
preparations were assessed by routine cytogenetics: karyotyping
involves only metaphase cell analyses and in the samples tested,
the abnormalities were simply not present in the metaphase cells
that could be analyzed. Other reasons for the discrepancy between
the karyotyping and aCGH data might include the poor quality of
metaphases or the loss of the aberrant clone during the in vitro
preparation, but given our observations, these seem less plausible.
Importantly, the DNA used for the aCGH was extracted from cells
obtained at the same time as those used for the karyotyping and
FISH experiments and therefore the possibility of clonal evolution
can also be ruled out. It could be argued that although the cells
were obtained at the same time, those used for aCGH were frozen
immediately and then processed for DNA extraction, whereas the
ones used for karyotyping were cultured. However, the culture
times were never longer than 48 hours, with approximately 50%
of the samples being processed after 24 hours of culture. It is
unlikely that the leukaemic clone/s would have evolved in such a
limited time. It is though possible that the use of a suboptimal
medium could result in the selective loss of tumour cells and the
cells analyzed in classical cytogenetics are only normal surviving
cells.
aCGH Study of Paediatric AML
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The observation that the CNAs appeared to occur only in
interphase nuclei in six out of the seven patient samples followed
up by FISH prompted us to investigate whether this was related to
the proliferative status of the cells,. The proliferation study, using
anti-pKi-67, demonstrated that the majority (94–100%) of nuclei
carrying the abnormality were also negative for the proliferation
marker and were therefore in a non-proliferative state. On the
other hand, only 69–75% of the nuclei without imbalances were
anti-pKi-67 negative. We have shown that the proportion of non-
dividing cells carrying the CNAs were significantly higher (at 99%
confidence in a one tailed test) than the percentage of non-dividing
cells karyotypically normal in each sample. Interestingly, in patient
no. 1, where two of the 13 metaphases analyzed presented with an
extra chromosome 7, both nuclei were pKi-67 positive as
expected. It is possible that these represent slowly-dividing cells
rather than cells actively proliferating at a normal rate, therefore
could not be identified by chromosome banding analysis. It might
be relevant to note that the original cytogenetic analysis on this
patient was performed on 15 metaphases, therefore the abnormal
clone might have been missed due to the relatively low number of
cells analysed in this case. Perhaps increasing the culture time from
the conventional 24–48 hours would favour the recruitment of a
higher number of metaphases showing the abnormalities, allowing
the leukaemic ‘‘slowly dividing’’ cells to reach cell division.
The detection of CNAs in AML with reported normal
karyotype is not a novel finding and our data are comparable to
those of Armengol et al. [21] who identified by aCGH large
genomic imbalances in two out of 16 cases of childhood AML,
although only three patients of this series had a normal karyotypes.
In a previous study, Tyybakinoja et al [16] also identified cryptic
copy number changes in 15% of adult AML cases with reported
normal karyotype. CNAs undetected by G-banding have been
revealed by Karst et al. [22] not only in normal karyotype AML,
but also in AML patients with reported monosomy 7 or trisomy 8
in a total of 34% of cases. Furthermore, since the introduction of
interphase FISH to complement the cytogenetic analysis in
diagnostic laboratories in the early 1990s, discrepancies between
karyotypes and observations of cell nuclei have been reported.
This has often been attributed to the analyses being conducted on
two different cell populations, dividing versus non-dividing, the
assumption being that interphase FISH was performed on non-
dividing cells. Following this assumption, Karst et al [22] came to
the conclusion that the chromosomal aberrations they detected in
the AML patients were restricted to the in vitro non-proliferating
population of tumor cells. However, for the first time, our study
has investigated the proliferating status of leukemic cells carrying
the CNAs. Using indirect immunofluorescence to reveal the Ki67
proliferation marker, we have generated experimental evidence to
Table 2. Summary of FISH results for all AML paediatric patients reported in this study.
Pt Chr Probe
Genomic Location
(hg35)
Number of
metaphases
observed by
FISH Percentage of interphase cells showing CNAs*
Co-existence of CNAs
involving different genomic
regions in the same clone
Single copy
loss
Gain of an
extra copy
Gain of two
extra copies
Gain of three
extra copies
1 7 p7t.1 7 cen 4 0.0 40.9 (4.866.8) 1.8 (060) 0.0 Yes: confirmed by FISH
8 D8Z2 8 cen 3 0.0 26.4 (1.360.6) 0 0.0
2 19 RP11-197O4 19p13.2 (10,509,359-
10,680,459)
0 0.0 48.5 (4.766.6) 2.9 0.0 ND
5 9 RP11-399H11 9q34.3 (131,495,347-
131,716,718)
2 0.0 14.4 (2.863.4) 0.0 0.0 ND
11 7 RP11-193I7 7q32.1 (130,884,337-
131,060,545)
0 80.1 (2.863.4) 0.0 0.0 0.0 ND
8 RP11-16G11 8q24.13 (122,320,844-
122,475,611)
0 0.0 66.0 (3.860.8) 0.0 0.0
16 CTD2515A14 16p12 (24,657,417-
24,876,429)
1 79.9 (3.861.2) 0.0 0.0 0.0
12 15 RP11-485O10 15q21.1 (46,628,904-
46,803,043)
0 28.0 (2.962.4) 0.0 0.0 0.0 ND
19 4 RP11-45F23 4q35.2 (190,867,466-
191,015,883)
0 66.8 (2.763.4) 0.0 0.0 0.0 Yes: confirmed by FISH
13 RP11-383H17 13q32.2 (97,344,722-
97,505,793)
0 0.0 55.1 (3.965.0) 14.0 (0.660.6) 0.9 (060)
*The percentage of cells presenting CNAs is indicated, taking into account the cut-off levels established using normal controls. In brackets: cut off levels (mean % of
control 62x st dev). The values shown are the result of the FISH analysis performed on at least 200 nuclei per patient. ND=not done.
doi:10.1371/journal.pone.0020607.t002
Figure 1. aCGH results of patients no. 1 (A) and 11 (B). On the Y-axis: mean fluorescence ratio; on the X-axis: ordered chromosomal location.
Results from the test versus reference and dye-swap experiments are shown in blue and pink, respectively. (A): genomic gains involving
chromosomes 7 and 8 are detected in the sample from patient no. 1 and are indicated by the red arrows. The subtle ratio changes are attributable to
mosaicism (see FISH results). (B): genomic losses involving 7q and 16p12 are detected in the sample from patient no. 11 and are indicated by the
green arrows; a gain involving 8q is indicated by the red arrow.
doi:10.1371/journal.pone.0020607.g001
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support the hypothesis that cryptic CNAs are largely confined to
either quiescent or senescent cells.
Clinically, one key question is whether the CNAs identified in
the patients with apparently normal karyotype and the observation
that they occur predominantly in cells that are not actively
proliferating confers any additional diagnostic or prognostic value
when evaluating AML patients. In other words, is it clinically
relevant that non-proliferating cells have chromosomal aberra-
tions? Further studies, beyond the scope of this report should be
aimed at investigating these aspects of AML biology. Tradition-
ally, the prognostic value of a normal karyotype in AML cases has
been considered intermediate [2,4]. However, the ability to detect
cryptic abnormalities has indicated that such assertions drawn
from a reported normal karyotype, are not always correct. For
example, patients who carry a cryptic partial duplication of the
MLL gene (11q23.3) have an unfavourable prognosis whereas
those with mutations of the transcription factor C/EBPa (19q12.1)
are usually associated with favourable clinical outcome [7,8].
Mutations of the FLT3 gene (13q12.2) are again poor prognostic
factor whereas patients with a mutation in the NPM1 gene (5q35.1)
as the sole abnormality have a better prognosis [9,23]. In the
patient cohort reported in the current study, the CNAs identified
did not harbour any of these prognostic marker genes and there
was no clinical outcome data available that would allow conclusive
links to prognosis to be made. The prognostic value of CNAs
detected by aCGH is supported by the study by Armengol et al.
[21], who made a general conclusion that four or more genomic
imbalances correlated with poor patient outcome in those with a
normal karyotype. Furthermore, it should be noted that in clinical
practice a copy number alteration equal or above the FISH cut-off
of 6% is believed to have an impact [24,25].
Our original observation that CNAs in patients with normal
karyotypes occur predominantly in cells that are not actively
proliferating should be taken in consideration when a correlation
with clinical outcome is attempted. Furthermore, our aCGH
assay, combined with interphase FISH, has enabled us to detect a
range of cells with various degrees of aneuploidy within the same
sample (chromosome 7 in patient no. 1, chromosome 19 in patient
no. 2 and chromosome 13 in patient no. 19), clearly showing
evolution of leukemic clones. The proliferation test was performed
Table 3. Summary of combined immunofluorescence and FISH results for 4 paediatric patients.
%Nuclei with 2 signals (absolute number of nuclei) % Nuclei with 3 signals (absolute number of nuclei)
Pt no. Chromosome Ki-67 positive Ki-67 negative Ki-67 positive Ki-67 negative
1 7 26 (58) 74 (170) 2 (3) 98 (118)
2 19 25 (32) 75 (98) 6 (5) 94 (68)
5 9 29 (45) 71 (110) 5 (2) 95 (38)
11 8 31 (24) 69 (55) 0 (0) 100 (101)
doi:10.1371/journal.pone.0020607.t003
Figure 2. Representative FISH images confirming CNAs in the nuclei of patient samples. (A) Dual-colour FISH signals on nucleus of patient
no. 1 confirm trisomy 7 and trisomy 8 in the same clone. Green signals correspond to chromosome 7 centromere, and red signals correspond to
chromosome 8 centromere. (B) Trisomy 19 is shown on a nucleus of patient no, 2 using probe RP11-197O4 (hybridization signals in red). (C) Three red
signals corresponding to probe RP11-399H11confirm the presence of three copies of 9q in patient no. 5. (D, E and F) FISH performed on patient
no. 11 confirmed: (D) a monosomy of 7q22 as shown by the presence of one red hybridization signal corresponding to probe RP11-193I7; (E) a
trisomy of 8q24.13 as shown by the presence of three red signals corresponding to probe RP11-16G11 and (F) a monosomy of 16p12 as shown by
one red signals corresponding to probe CTD-2515A14. (G) In patient no. 12, monosomy of 15q21.1 is shown by one red signal corresponding to
probe RP11-485O10 (H) Dual-colour FISH on a nucleus from patient no. 19 confirms the presence of a trisomy for 13q32.2 (three red signals
corresponding to probe RP11-383H17) and monosomy of 4q35.2 (one green signal corresponding to RP11-45F23) in the same leukaemic clone.
doi:10.1371/journal.pone.0020607.g002
aCGH Study of Paediatric AML
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20607
on two of these samples (patient nos. 1 and 2) and showed that the
aneuploidies were largely, but not only, confined to the pKi-67
negative cells in these cases. This implies that it is still possible for
that small percentage of pKi-67 positive cells to evolve with respect
to the acquisition of additional changes.
Our aCGH system at ,3 Mb resolution might be considered
now obsolete, since higher resolution platforms are continuously
made available and are currently being introduced in the
laboratory practice. Nevertheless, our system was sufficient to
reveal large genomic gains or losses. However, the prognostic
value of these findings and the possible impact in the clinical
practice needs to be addressed.
Our data may also offer some practical information in terms of
clinical laboratory evaluation of leukaemia cases: (i) longer culture
times might improve the detection of abnormalities in slowly
dividing cells; (ii) aCGH could be considered as a routine tool
alongside optimized karyotyping or targeted FISH for the
evaluation of AML cases.
aCGH cannot be a replacement for the cytogenetic approaches
in AML because it cannot detect truly balanced rearrangements or
give positional information. However, it is a powerful tool for the
detection of cryptic unbalances that may be missed cytogenetically.
In summary, our study has added to a growing body of evidence
showing that a significant proportion of patients with AML
harbour cryptic CNAs. Importantly, we have also shown that these
CNAs are mostly confined to interphase cells. The novelty of our
study resides in the finding that these interphase cells are in
quiescent or senescent status. Our findings will need to be
exploited further not only towards the establishment of more
suitable diagnostic tools, but also towards a better understanding
of the biology of AML with apparently normal cytogenetics.
Materials and Methods
Patients and ethics statement
Bone marrow samples from 23 paediatric patients with AML,
all with normal karyotypes, were used for the aCGH study. A
single control DNA sample from the peripheral blood lymphocytes
of a healthy subject (sex matched) was routinely used in the lab for
aCGH experiments. Three different control samples from
peripheral blood lymphocytes of healthy individuals were used
for FISH. Clinical and cytogenetic details of all the patients
analyzed in this study are summarized in Table 1. Patient nos. 1–5
were contributed by the Paediatric Clinic, San Gerardo Hospital,
Monza, Italy. Patient nos. 6–23 were contributed by the
Oncogenetic Laboratory, Children’s University Hospital, Giessen,
Germany. Informed consent for the use of blood or bone marrow
samples for research purposes was obtained from all individuals or
their parents. Ethical approval to work on these samples was
obtained by the Brunel Ethics Committee.
aCGH protocol
Genomic DNA was extracted using the PUREGENETM DNA
isolation kit (Gentra System, Minneapolis, USA), according to
manufacturer’s instructions. Reference and test genomic DNAs
were sonicated and purified using microcon columns (Millipore,
Watford, UK), according to manufacturer’s instructions. 2 mg of
each purified DNA was labelled overnight, with the appropriate
cyanine dye, Cy3dCTP or Cy5dCTP (Amersham Pharmacia, GE
Healthcare, Buckinghamshire, UK), using the BioPrime DNA
labelling kit (Invitrogen, Inc., Carlsbad, California, USA). Two
aCGH tests were performed for each patient: in the first, the
patient genomic DNA was labelled with Cy5 dye and the normal
DNA reference with Cy3 dye; in the second, a ‘‘dye-swap’’
experiment was carried out where the patient sample was labelled
with Cy3 dye and the normal reference with Cy5 dye. Labelled
samples from the test and reference samples were combined and
hybridized to 1 Mb density, large-insert clone arrays prepared at
The Wellcome Trust Centre for Human Genetics, Oxford, UK
using the 1 Mb clone set obtained from The Wellcome Trust
Sanger Institute (Cambridge, UK), as previously described [26].
The fluorescence intensity data were collected by scanning the
arrays in a GenePix 4000B scanner (Molecular Devices, USA),
using GenePix Pro 4.1 software (Axon Laboratories). The data
were stored in a GenePix Results file (GRP) and imported into
Microsoft Excel. A series of customized Macro files were used in
Excel. The fluorescence intensity of the local background was
subtracted from the raw intensity of each spot. The reference
versus test DNA spot intensity ratio was calculated (i.e. Cy5/Cy3)
and the median of all the spot ratios within each block was
Figure 3. Example of Immuno-FISH performed on cells from patient no. 2. Anti-pKi-67 antibody is shown in green, whereas hybridization
signals corresponding to the chromosome 19 specific probe RP11-197O4 is shown in red. (A): the nucleus with two FISH signals is pKi-67 positive,
whereas the nucleus with three FISH signals is pKi-67 negative (B): the metaphase with two FISH signals is pKi-67 positive, whereas the nucleus with
three FISH signals is pKi-67 negative.
doi:10.1371/journal.pone.0020607.g003
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calculated. Normalization of each spot intensity ratio was achieved
by dividing the intensity ratio by the median of all spot ratios
within each block. For each clone, the mean and standard
deviation (SD) across the identical triplicate were calculated. Any
spot with a SD.0.2 was discarded from the analysis. If two of the
triplicate spots representing a clone had a SD.0.2, the clone was
discarded from the analysis. The mean normalized fluorescent
intensity ratios were plotted in chart form, from which clones
representing gains and losses of chromosomal material were
identified.
Definition of the extent of CNAs
CNAs were detected visually using lower and upper threshold
values of 0.8 and 1.2 to indicate loss and gain respectively. These
values were calculated using the global thresholding method
previously described [26,27]. We would consider at least three
contiguous probes above/below the threshold, that would
correspond to a genomic fragment of at least 2 Mb in size.
FISH analysis
FISH was performed on archival fixed cell and chromosome
suspensions prepared from the bone marrow of the patients and
from the peripheral blood of the healthy individuals. These same
archival suspensions were used previously for the chromosome
analysis that defined the karyotype in all patients analyzed. The
bone marrow cells used for these analyses were typically cultured
in RPMI-1640 medium with 20% foetal calf serum for 24 hours
(patient nos. 6, 9, 10, 19–21) or 48 hours (patient nos 1–5, 7, 8,
11–18, 22, 23) prior to harvesting, whereas the peripheral blood
cultures were set up for 72 hours prior to harvesting according to
existing protocols [28]. Briefly, colcemid is added 30 minutes prior
to harvesting in all cases, samples are then treated with hypotonic
solution for 15–30 minutes, fixation follows using the standard
solution (three parts of methanol and one part of acetic acid). Cells
and chromosomes suspensions are then dropped onto clean
microscope slides and used for chromosome banding or FISH.
The cytogenetic analysis was carried out in two different
laboratories: (i) Centro Ricerca Tettamanti, Paediatric Clinic,
San Gerardo Hospital, Monza, Italy (patient nos 1–5) and (ii)
Oncogenetic Laboratory, Children’s University Hospital, Giessen,
Germany (patient nos. 6–23). The karyotypes were not reviewed
centrally, however they were assessed and checked by two
experienced cytogeneticists in each centre. Details of the FISH
probes used are given in Table 2. Probes were labelled by nick
translation using either biotin-16-dUTP or digoxigenin-11-dUTP
and hybridized as previously described [29] Dual colour detection
was obtained using Texas red conjugated avidin and anti-
digoxigenin FITC conjugated antibodies. Microscope analysis
was performed using fluorescence microscope Zeiss Axioplan2
Imaging equipped with specific band pass filter wheel and Sensys
cooled CCD camera. Image capture and enhancement was
performed using Smart Capture 2 software (Digital Scientific,
Cambridge, UK).
Interphase FISH: Calculation of cut-off values and
statistical analysis
CNAs in patients samples were established after comparison
with interphase FISH performed on normal controls according to
methods published previously [30]. Briefly, a monosomy or a
trisomy is assessed when the percentage of cells with one or three
FISH signals is greater than the mean % value of the controls 62
SD. A minimum of 200 nuclei were counted in each sample (both
normal controls and patient samples).
Indirect Immunofluorescence
FISH slides were washed with PBS and monoclonal anti-pKi-67
(Novacastra, Newcastle Upon Tyne, UK) was applied to the slides
for 30 min at 37uC. Secondary swine anti-rabbit antibody
(DAKO, Denmark), conjugated to fluorescein isothiocyanate
(FITC) was then applied to the slides for 30 min at 37uC. Images
were captured using a Zeiss microscope. A minimum of 200 nuclei
were analyzed in each sample.
Proliferation test: statistical analysis
We chose to use the hypothesis test on the difference in
population proportions [31]. This statistical test is used to
determine whether the difference between two proportions is
significant. Four different patients were considered. For each
patient, the proportion of pKi-67 negative cells was compared
between the population of nuclei with two signals and the
population of nuclei with three signals. We showed that, for every
patient, the proportion of pKi-67 negative cells is statistically
higher in the population of nuclei with three signals. The
application of the hypothesis test applied to our datasets can be
viewed in table S1.
Supporting Information
Figure S1 Examples of FISH using a centromeric probe specific
for chromosome 7 (7cen) on patient no. 1. Two red signals are
clearly visible in the metaphase, whereas three fluorescent signals
are present in the nucleus in the same sample.
(TIF)
Table S1 Using a one-sided hypothesis test, with a null
hypothesis that p1 = p2, and an alternative hypothesis that
p1,p2, at 99% confidence, the critical test statistic is 2.33. Since
the test statistics above are all greater than 2.33, then we can reject
the null hypothesis in all cases. Note: it is often recommended that
this test only be applied when both the number of successes and
the number of failures is at least 5 in both populations. Although
this is strictly not satisfied in population 2 above, it is satisfied for
the cell population as a whole. Also, if the number of failures in
population 2 (i.e. the number of Ki-67 positive cells with 3 signals)
was 5 for all patients (a result which is clearly not as significant as
the result above), then the result would still be statistically
significant at 99% confidence for all patients except patient 5. For
patient 5 it would be statistically significant at 98% confidence.
(DOC)
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